AESICA ANNOUNCES KEY NORTH AMERICAN APPOINTMENT
One of Europes leading CMOs, Aesica, has announced a key addition to its commercial team as it looks to strengthen its position in North America.
One of Europe’s leading CMOs, Aesica, has announced a key addition to its commercial team as it looks to strengthen its position in North America.
Dr. Emma Mickley has been promoted from her role as Director of Business Development into the newly created position of Vice President of Corporate Business Development. Emma will be based in San Diego, California, and will support the company in growing its share of the North American contract manufacturing market.
Speaking about her promotion, she said: “This is an exciting time to be representing Aesica in North America. This region is a key strategic priority for us for the forseeable future and we are 100 per cent committed to shaping and positioning our business to meet the needs of mid-size and emerging pharma in Canada and The States”.
“The fact that genuine pharmaceutical innovation is now increasingly challenging has led big pharma to partner with small and mid size companies in developing NCEs. Taking advantage of the limited window of patent exclusivity has never been more critical, and this is where we come in”.
“Accelerating speed to market is our strength, and as an integrated CMO we offer customers in North America a fast track from development to clinical trials and onwards to market. Where we really excel is in helping emerging and mid size pharma companies get their products to clinical trials fast, before they pass the baton to big pharma, who we work with to drive formulations through to scale-up stage.”
Emma will support the company’s plans to extend its manufacturing base to cater to the North American market and capitalize on its strong core of strategic accounts within mid-sized and emerging pharma companies. Emma’s role will be central to the success of Aesica in the region, as the company expands to become the pharma industry’s partner of choice for the development and manufacture of APIs and formulated products.
Dr. Alan Raymond, Sales and Marketing Director, Aesica Pharmaceuticals, said: “I am delighted to announce Emma’s appointment into this new senior role. Expanding our presence in North America is absolutely vital to our growth on a global scale, and this position is key to us achieving that goal. Emma’s contribution will play no small part in helping us achieve our ambitions to become a trusted partner to the most innovative and respected names in pharma.”
With Emma on board to oversee the needs of the North American market, Aesica will offer the pharma sector a single point of contact across the key stages of drug development. Its integrated service includes API scale up, formulation development, manufacture of CT supplies to commercial scale and final dosage form manufacture.
For more information about Aesica, please visit www.aesica-pharma.com
Related News
-
News Women in Pharma: Hiring Across the Gender Divide
In our monthly series, we interview women from across the pharmaceutical industry and supply chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
Sponsored Content Ashwagandha and Herbal Medicines: Pharma’s Next Big Opportunity
Herbal medicines and nutraceuticals have seen a surge in interest since the onset of the COVID-19 pandemic. Driven by patient interest in prioritising personalised and integrative medicines, the herbal ingredients industry is now faced with concerns pe... -
News Identifying Alzheimer’s Disease biomarker proteins with whole blood tests
A University of Manchester spin-out pharmaceutical company, PharmaKure, has reported successful study results for the quantification of Alzheimer’s Disease biomarker proteins with a whole blood test. -
News Bill & Melinda Gates Foundation to boost mRNA vaccine initiatives in Africa with USD $40m
To address vaccine inequality and accessibility issues, the Bill & Melinda Gates Foundation aims to deliver USD $40m to various biotech companies and vaccine manufacturers in support of mRNA vaccine development. -
News Updated – Changing abortion pill access according to the US FDA and Supreme Court
After the approval of the medical abortion pill, mifepristone, by the US FDA, states across the USA approach the distribution of the pill differently, some ruling against allowing access to the drug. -
News Revolutionising cancer treatment with mRNA-based therapeutics
Global market for mRNA-based oncology therapeutics expected to reach USD $2 billion by 2029, with promising results for the combination of mRNA candidates with immune checkpoint inhibitors to treat solid tumours. -
News Breaking Barriers: Innovations in Oral Solid Dose Form Bioavailability
The effectiveness of a medication often hinges on its bioavailability – the rate and extent at which the active ingredient is absorbed into the bloodstream. When it comes to oral solid dose forms, such as tablets and capsules, the challenge lies ... -
News Choosing the Right CDMO Partner: A Comprehensive Guide
Finding the right partner for the development and manufacturing of your pharmaceutical or biopharmaceutical products is paramount. This is where Contract Development and Manufacturing Organizations (CDMOs) step in, offering their expertise and infrastr...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance